Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Patrick DalyChronic Lymphocytic Leukemia | February 21, 2024
Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up.
Read More
Patrick DalyChronic Lymphocytic Leukemia | February 21, 2024
NX-2127, a first-in-class therapy, induced BTK degradation and clinical responses in CLL resistant to BTK inhibitors.
Melissa BadamoChronic Lymphocytic Leukemia | February 22, 2024
MRD-directed ibrutinib plus venetoclax therapy improved PFS in patients with CLL.
Justin Taylor, MDChronic Lymphocytic Leukemia | February 14, 2024
The study defined mutations that develop resistance to BTK inhibitors and evaluated the BTK degrader NX-2127 in CLL.
Blood Cancer TalksBlood Cancer Talks | January 31, 2024
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Mariia Mikhaleva, MDChronic Lymphocytic Leukemia | January 26, 2024
The presence of two or more mutations are associated with high-risk cell features.
Advertisement
Chaitra Ujjani, MDChronic Lymphocytic Leukemia | January 22, 2024
Chaitra Ujjani, MD, discusses research on the incidence and management of COVID-19 infections in patients with CLL.
Melissa BadamoChronic Lymphocytic Leukemia | January 22, 2024
Some mutations are associated with shorter event-free survival in low-risk, early-stage CLL.
Melissa BadamoChronic Lymphocytic Leukemia | January 18, 2024
The updated analysis found that combining rituximab with ibrutinib did not provide additional treatment benefit.
Blood Cancers Today Staff WritersChronic Lymphocytic Leukemia | January 16, 2024
The therapy is currently under investigation in multiple clinical trials.
Melissa BadamoChronic Lymphocytic Leukemia | February 2, 2024
The label update includes progression-free survival results from the ALPINE phase III trial.
Leah SherwoodChronic Lymphocytic Leukemia | January 5, 2024
Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain.
Melissa BadamoChronic Lymphocytic Leukemia | December 20, 2023
The median PFS was 10 months, and the 12-month OS rate was 74.7%.
Melissa BadamoChronic Lymphocytic Leukemia | December 20, 2023
The matching-adjusted indirect comparison estimated the effect of pirtobrutinib versus venetoclax in cBTKi-pretreated CLL.
Melissa BadamoChronic Lymphocytic Leukemia | December 20, 2023
The study compared ibrutinib plus venetoclax and ibrutinib monotherapy with fludarabine, cyclophosphamide, and rituximab.
Leah SherwoodMeeting News | December 18, 2023
DDX3X dysregulation is involved in the progression of CLL by facilitating NOTCH1 mRNA translation
Leah SherwoodMeeting News | December 18, 2023
Researchers said there was a need for potentially more effective one-time-only treatment options.
Jennifer R. Brown, MD, PhDChronic Lymphocytic Leukemia | December 16, 2023
Dr. Brown presented updated results from the ALPINE study at ASH 2023.
Patrick DalyChronic Lymphocytic Leukemia | December 16, 2023
ELEVATE-TN enrolled 535 patients, of which 179 received acalabrutinib.
Jennifer Woyach, MDChronic Lymphocytic Leukemia | December 17, 2023
Dr. Woyach joined Chadi Nabhan, MD, MBA, FACP, to discuss the novel BTK inhibitors pirtobrutinib and LP168.
Advertisement
Advertisement
Editorial Board